NCT01424241 is a Phase 4 clinical trial of Sandostatin LAR in Acromegaly, sponsored by Columbia University.

Who is sponsoring NCT01424241?

NCT01424241 is sponsored by Columbia University.

What drugs are being tested in NCT01424241?

Interventions in NCT01424241: Sandostatin LAR.

What condition does NCT01424241 study?

NCT01424241 studies Acromegaly.

Is NCT01424241 still recruiting?

NCT01424241 is currently completed. Last updated 22 July 2024.

Are results published for NCT01424241?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-07-22 · How we verify

NCT01424241

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range

Completed Phase 4 Results posted Last updated 22 July 2024

What this trial tests

Phase 4 trial testing Sandostatin LAR in Acromegaly in 21 participants. Completed in 1 January 2014.

Timeline

1 October 2006

Primary endpoint
1 March 2013

1 January 2014

Quick facts

Lead sponsor	Columbia University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 October 2006
Primary completion	1 March 2013
Estimated completion	1 January 2014
Sites	1 location across United States

Drugs / interventions tested

Sandostatin LAR — full drug profile →

Conditions studied

Acromegaly — all drugs for Acromegaly →

Sponsor

Columbia University

Who can join

18 and older, any sex, with Acromegaly. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

IGF-1 Level on Sandostatin LAR
Time frame: Up to 9 months
Mean IGF-1 level on treatment with Sandostatin LAR in whole population and responders (normal IGF1) and non responders(elevated IGF-1)

Sponsor's own description

This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF-1) normalization into current IGF-I normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition parameters in patients with active acromegaly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sandostatin LAR

Trials testing the same drug.

NCT05364944 — A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Ac · Phase 1 · terminated

Other recruiting trials for Acromegaly

Currently open trials in the same condition.

NCT07037420 — ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly · Phase 2 · recruiting
NCT05401084 — Diet in the Management of Acromegaly · NA · recruiting
NCT05131100 — Korean Regulatory Post Marketing Surveillance for Somavert · recruiting
NCT05964712 — Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study · recruiting
NCT03158090 — The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01424241 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 22 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01424241.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing